Andrew Pollack reports:
President Obama is pushing for a last-minute change in the final health care bill that would shorten the time that expensive biotechnology drugs would be shielded from generic competition, pharmaceutical industry officials said Thursday.
Any White House intervention would be welcome news to generic pharmaceutical companies, as well as to some consumer groups, insurers and big employers, which have complained that the proposed House and Senate bills would not allow for robust competition.
If you’ve read my previous posts on pharma and research, you know I think this is a good thing. It also has the side benefit of reducing the cost of health care significantly.
Expect pharma to release the hounds over this.